Table 1.

Studies regarding (IV or CVI or IVT) administration of tigecycline in Acinetobacter baumannii meningitis/ventriculitis (I).

Reference	(10)	(11)	(11)	This study
Age	25	48	52	55
Sex	male	male	male	male
Underlying disease(s)	Pilocytic astrocytom hydrocephalus	Vertebral trauma	Lumbar disk herniation	Intracerebellar hemorrhage, CSF, hydrocephalus
Foreign body	EVD	Spinal instrumentation	None	EVD
Days from admission to diagnosis	11	10	9	26
Antimicrobial susceptibilities AB Colimycin;	Susceptible to TGC (MIC = 3.2 μg/mL); MDR	Susceptible to netilmicin, TGC(MIC = 0.38 μg/mL); MDR	Susceptible to netilmicin, TGC(MIC = 0.38 μg/mL); MDR	Susceptible to TGC(MIC = 16 μg/mL); XDR
Current antimicrobial regimens	TGC and colimycin and meropenem	TGC, Netilmicin, and meropenem	TGC, Netilmicin	TGC, cefoperazone-sulbactam, amikacin
IV/CVI/IVT, tigecycline	IV, 50 mg/q12h	IV, 50 mg/q12h	IV, 50 mg/q12	IV, 100 mg/q12h CVI, 10 mg/q12h IVT, 2 mg/q12h
Co-administered antibiotics	Colimycin IV, 9MIU/q24	Netilmicin IV, (400 mg/q24h) Meropenem IV, (2g/q8h)	Netilmicin IV, (400 mg/q24h) Meropenem IV, (2g/q8h)	Cefoperazone-sulbactam IV, (2g/q8h)
Days to CSF sterilization	23	21	21	12
Toxicity	None	None	None	None
Infection outcome	Cured	Cured	Cured	Cured
Survival	Yes	Yes	Yes	Yes

CSF, cerebrospinal fluid; MIC, minimum inhibitory concentration; EVD, external ventricular drain; MDR, multidrug resistant; XDR, extensively drug-resistant; TGC, tigecycline; q8h, every 8 h; q12h, every 12 h; q24h, every 24 h; IV, intravenous; CVI, continuous ventricular irrigation; IVT, intraventricular.